Theravance Falls on FDA Meeting Scope (AP via Yahoo! Finance)
Shares of Theravance Inc. hit their lowest point since 2005 on Friday, after the biopharmaceutical company reported better-than-expected fourth-quarter results but analysts said the scope of next week's FDA review of its staph-infection drug appears wider than previously thought.

Abbott Receives FDA Approval For SIMCOR(R) (Niaspan(R) / Simvastatin), A Novel Combination Medicine For Comprehensive ... (Medical News Today)
Abbott received U.S. Food and Drug Administration (FDA) approval for SIMCOR(R), the first fixed-dose combination of two widely prescribed cholesterol therapies, Niaspan(R) (Abbott's proprietary niacin extended-release) and simvastatin.